|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
JP2022500385A
(ja)
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EA202190749A1
(ru)
|
2018-09-10 |
2021-07-09 |
Мирати Терапьютикс, Инк. |
Способы комбинированной терапии
|
|
EP3849537B1
(en)
|
2018-09-10 |
2024-10-23 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
MX2021002804A
(es)
|
2018-12-05 |
2021-07-15 |
Mirati Therapeutics Inc |
Terapias de combinacion.
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
MX2022002465A
(es)
|
2019-08-29 |
2022-05-19 |
Mirati Therapeutics Inc |
Inhibidores de kras g12d.
|
|
WO2021061749A1
(en)
|
2019-09-24 |
2021-04-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
IL300309B2
(en)
|
2020-08-12 |
2026-03-01 |
Genentech Inc |
Synthesis of quinazoline compounds
|
|
EP4210833A4
(en)
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
WO2022068921A1
(zh)
*
|
2020-09-30 |
2022-04-07 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
WO2022105859A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
JP2023553492A
(ja)
|
2020-12-15 |
2023-12-21 |
ミラティ セラピューティクス， インコーポレイテッド |
アザキナゾリン汎ＫＲａｓ阻害剤
|
|
EP4262803A4
(en)
|
2020-12-16 |
2025-03-12 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
KR20230136636A
(ko)
*
|
2021-02-09 |
2023-09-26 |
메드샤인 디스커버리 아이엔씨. |
피리미딘 방향족 환 화합물
|
|
BR112023016299A2
(pt)
*
|
2021-02-16 |
2023-11-28 |
L Livermore Nat Security Llc |
Composições e métodos para inibir kras
|
|
MX2023010430A
(es)
*
|
2021-03-12 |
2023-09-12 |
Bristol Myers Squibb Co |
Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
|
|
CN115160309B
(zh)
*
|
2021-04-07 |
2024-04-09 |
药雅科技(上海)有限公司 |
Krasg12c突变蛋白杂环类抑制剂的制备及其应用
|
|
CN115260214A
(zh)
*
|
2021-04-29 |
2022-11-01 |
药雅科技(上海)有限公司 |
稠环类krasg12d突变蛋白抑制剂的制备及其应用
|
|
CN117659051A
(zh)
*
|
2021-03-30 |
2024-03-08 |
上海德琪医药科技有限公司 |
Kras g12d蛋白抑制剂和其用途
|
|
US20250255868A1
(en)
*
|
2021-04-09 |
2025-08-14 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocyclic compound acting as kras g12d inhibitor
|
|
WO2022221386A1
(en)
*
|
2021-04-14 |
2022-10-20 |
Erasca, Inc. |
Selective kras inhibitors
|
|
EP4322954A4
(en)
*
|
2021-04-16 |
2025-01-29 |
Merck Sharp & Dohme LLC |
SMALL MOLECULAR INHIBITORS OF THE KRAS G12D MUTANT
|
|
MX2023012725A
(es)
*
|
2021-04-29 |
2024-09-23 |
Amgen Inc |
Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
|
|
US20250059205A1
(en)
*
|
2021-04-29 |
2025-02-20 |
Amgen Inc. |
Heterocyclic Compounds and Methods of Use
|
|
CN117222650A
(zh)
*
|
2021-04-30 |
2023-12-12 |
劲方医药科技(上海)有限公司 |
吡啶或嘧啶并环类化合物，其制法与医药上的用途
|
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ｒａｓ阻害剤及びその使用
|
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
CN115385938A
(zh)
*
|
2021-05-25 |
2022-11-25 |
江苏恒瑞医药股份有限公司 |
苯并嘧啶类化合物、其制备方法及其在医药上的应用
|
|
WO2022261154A1
(en)
*
|
2021-06-09 |
2022-12-15 |
Eli Lilly And Company |
Substituted fused azines as kras g12d inhibitors
|
|
BR112023025869A2
(pt)
*
|
2021-06-10 |
2024-02-27 |
Redx Pharma Plc |
Derivados de quinazolina úteis como inibidores de ras
|
|
WO2022262686A1
(en)
*
|
2021-06-13 |
2022-12-22 |
Jingrui Biopharma Co., Ltd. |
Kras g12d inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
EP4363412A4
(en)
*
|
2021-06-30 |
2025-05-14 |
Dana-Farber Cancer Institute, Inc. |
Small-molecule inhibitors of the KRAS G12D mutant
|
|
IL310291A
(en)
|
2021-07-23 |
2024-03-01 |
Theras Inc |
Compositions and methods for inhibition of ras
|
|
KR20240041917A
(ko)
|
2021-07-27 |
2024-04-01 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
|
US20240409558A1
(en)
*
|
2021-09-13 |
2024-12-12 |
Biomea Fusion, Inc. |
Irreversible inhibitors of kras
|
|
WO2023061294A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
再鼎医药(上海)有限公司 |
含氮杂环类衍生物调节剂、其制备方法及应用
|
|
WO2023061463A1
(zh)
*
|
2021-10-15 |
2023-04-20 |
广东东阳光药业有限公司 |
新的嘧啶并吡啶化合物、其药物组合物及其用途
|
|
WO2023072188A1
(zh)
*
|
2021-10-29 |
2023-05-04 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
CN116253748A
(zh)
*
|
2021-12-09 |
2023-06-13 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
CN118556063A
(zh)
*
|
2022-01-21 |
2024-08-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
EP4371991A4
(en)
*
|
2022-01-21 |
2025-02-26 |
Usynova Pharmaceuticals Ltd. |
Benzopyrimidine compounds and use thereof
|
|
AU2023216698A1
(en)
*
|
2022-02-03 |
2024-06-13 |
Mirati Therapeutics, Inc. |
Quinazoline pan-kras inhibitors
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
WO2023151621A1
(zh)
*
|
2022-02-11 |
2023-08-17 |
泰励生物科技（上海）有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
EP4479398A1
(en)
*
|
2022-02-16 |
2024-12-25 |
Amgen Inc. |
Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
CN114573438A
(zh)
*
|
2022-03-31 |
2022-06-03 |
上海应用技术大学 |
一种单氟氯/溴代丙酮类化合物及其制备方法
|
|
CN116891488B
(zh)
*
|
2022-04-11 |
2025-12-12 |
成都海博为药业有限公司 |
稠环化合物、包含其的药物组合物及应用
|
|
CA3247639A1
(en)
|
2022-05-06 |
2023-11-09 |
PAQ Therapeutics Inc. |
CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2023244713A1
(en)
*
|
2022-06-16 |
2023-12-21 |
Ensem Therapeutics, Inc. |
Quinazoline derivatives, compositions and methods thereof
|
|
WO2024008068A1
(en)
*
|
2022-07-04 |
2024-01-11 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
US20250145631A1
(en)
|
2022-07-21 |
2025-05-08 |
Astellas Pharma Inc. |
Heterocyclic compound acting on g12d mutant kras protein
|
|
US20260035376A1
(en)
*
|
2022-08-05 |
2026-02-05 |
Theras, Inc. |
Compositions and methods for inhibition of ras
|
|
US20260042764A1
(en)
*
|
2022-08-05 |
2026-02-12 |
Theras, Inc. |
Compositions and methods for inhibition of kras
|
|
EP4570794A1
(en)
|
2022-08-09 |
2025-06-18 |
Astellas Pharma, Inc. |
Heterocyclic compound for inhibiting and/or inducing degradation of kras protein
|
|
JP2025526744A
(ja)
|
2022-08-11 |
2025-08-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｋｒａｓ阻害剤
|
|
AR130192A1
(es)
*
|
2022-08-12 |
2024-11-13 |
Astellas Pharma Inc |
Combinaciones antineoplásicas que comprenden quimioterapia
|
|
AR130191A1
(es)
|
2022-08-12 |
2024-11-13 |
Astellas Pharma Inc |
Combinaciones antineoplásicas que comprenden tratamiento dirigido
|
|
WO2024061333A1
(zh)
*
|
2022-09-21 |
2024-03-28 |
甘李药业股份有限公司 |
一种kras突变蛋白抑制剂、及其制备方法和应用
|
|
JP2025534419A
(ja)
*
|
2022-09-30 |
2025-10-15 |
トラスヴェダ リミテッド |
Ｋｒａｓ変異腫瘍に対する抗腫瘍活性を有する化合物
|
|
CN117886833A
(zh)
*
|
2022-10-13 |
2024-04-16 |
广东东阳光药业股份有限公司 |
一种嘧啶并吡啶化合物、其药物组合物及其用途
|
|
CN117263959A
(zh)
*
|
2022-10-24 |
2023-12-22 |
药雅科技(上海)有限公司 |
芳香类kras突变蛋白抑制剂的制备及其应用
|
|
CN120659773A
(zh)
|
2022-11-09 |
2025-09-16 |
锐新医药公司 |
化合物、复合物以及其制备方法和用途
|
|
CN116554208A
(zh)
*
|
2022-12-02 |
2023-08-08 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
WO2024158242A1
(ko)
*
|
2023-01-25 |
2024-08-02 |
주식회사 엔바이오스 |
Kras g12d 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물
|
|
KR20260041941A
(ko)
|
2023-03-15 |
2026-03-27 |
콴타 테라퓨틱스, 인크. |
Kras 조절 인자 및 이의 용도
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
AR133027A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un compuesto de quinazolina
|
|
CN119219668A
(zh)
*
|
2023-06-28 |
2024-12-31 |
广东东阳光药业股份有限公司 |
嘧啶并吡啶化合物、其药物组合物及其用途
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
AU2024337016A1
(en)
*
|
2023-09-08 |
2026-04-16 |
Tyligand Bioscience (Shanghai) Limited |
Ras inhibitor
|
|
CN121941690A
(zh)
|
2023-10-03 |
2026-04-28 |
Paq医疗公司 |
Kras蛋白水解靶向嵌合体
|
|
CN121969634A
(zh)
*
|
2023-10-08 |
2026-05-01 |
成都海博为药业有限公司 |
一种稠环化合物及应用
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
US20250114339A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
|
|
WO2025077770A1
(zh)
*
|
2023-10-10 |
2025-04-17 |
成都海博为药业有限公司 |
一种稠环化合物及在kras抑制剂方面的应用
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025085580A1
(en)
*
|
2023-10-17 |
2025-04-24 |
Windermere Therapeutics, Inc. |
Kras(g12d) inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|